お気に入りに追加
製品詳細
Synonyms
TNFRSF17, CD269, BCM, BCMA
Source
PE-Labeled Human BCMA, His Tag (BCA-HP2H2) is produced via site-specific conjugation of PE to Human BCMA, His Tag under optimal conditions with a proprietary technology. Human BCMA, His Tag is expressed from human 293 cells (HEK293). It contains AA Met 1 - Ala 54 (Accession # Q02223-1).
Predicted N-terminus: Met 1
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 9.6 kDa.
Conjugate
PE
Excitation Wavelength: 488 nm / 561 nm
Emission Wavelength: 575 nm
Application
Please note that this product is NOT compatible to streptavidin detection system.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, 0.5% BSA, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please protect from light and avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 6 months under sterile conditions after reconstitution.
ACRO Quality Management System
お客様はこちらも閲覧
データ表示
FACS Analysis of Blood Samples
After Fc receptor blockade, the whole blood only control (Figure A) and the whole blood spiked with CAR-T cells (Figures B, C, and D) were first stained with anti-CD45 antibody, anti-CD3 antibody, and PE-labeled Human BCMA/TNFRSF17 Protein, His Tag (Site-specific conjugation) (Cat. BCA-HP2H2), followed by 7-AAD staining. The data were analyzed using FCS Express 7 software (routinely tested). CAR-T cells were identified as PE-positive events within the live CD45⁺CD3⁺ (or CD45⁺) lymphocyte population. In panels B, C, and D, the proportions of CD45⁺ CAR⁺ cells were approximately 20%, 10%, and 1%, respectively, consistent with the theoretical spike‑in values of 22.71%, 11.66%, and 1.17%.
Protocol
Bioactivity-FACS
5e5 of the Anti-BCMA CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human BCMA Protein, His Tag (Cat. No. BCA-HP2H2) and negative control protein respectively, PE signal was used to evaluate the binding activity (QC tested).
Protocol
ユーザーレビュー コメントを投稿
バックグランド
最新の進展
医薬品開発の進捗- 英語名：
B-cell maturation protein
- カテゴリ：
- 市販の医薬品数：
8 詳細
- 治験医薬品数：
145 詳細
- 最新の開発ステージ：
Approved
お問い合わせ
メールアドレス
order.jp@acrobiosystems.com
お問い合わせ
グローバル：+1 800-810-0816(Toll Free)
医薬品候補ライセンス
